NewsBenzingaPasithea Therapeutics presenta el ensayo de escalada de dosis de fase I del inhibidor PAS-004; anuncia que no se observaron toxicidades limitantes de la dosis; ningún participante discontinuó PAS-004; no se observaron eventos de grado 3 o superior. Pasithea Therapeutics presenta el ensayo de escalada de dosis de fase I del inhibidor PAS-004; anuncia que no se observaron toxicidades limitantes de la dosis; ningún participante discontinuó PAS-004; no se observaron eventos de grado 3 o superior. Benzinga 2026.10.23 13:20 (GMT+0) Open on Benzinga Other news Here’s How Much You Would Have Made Owning Seagate Technology Hldgs Stock In The Last 20 Years Here's How Much $100 Invested In Copart 10 Years Ago Would Be Worth Today Lighter Supports weETH as Perpetual Futures Margin, With 1,000-Token Platform-Wide Cap Hottest toy for Christmas? Nvidia CEO plays with adorable Microduck robots, 20,000 sell AppFolio: Tailwinds Are Now Priced In After Recent Rebound (Downgrade) (NASDAQ:APPF) 'JetBlue Creditors Huddle With Restructuring Adviser as Bonds, Shares Sink'- WSJ
